References
- Hammerschlag MR. Advances in the management of Chlamydia pneumoniae infections. Expert Rev Anti Infect Ther 2003; 1: 493–503.
- Miyashita N, Fukano H, Niki Y et al. In vitro activity of telithromycin, a new ketolide, against Chlamydia pneumoniae. J Antimicrob Chemother 2001; 48: 403–5.
- Muller-Serieys C, Andrews J, Vacheron F et al. Tissue ki-netics of telithromycin, the first ketolide antibacterial. J Antimi-crob Chemother 2004; 53: 149–57.
- Törmäkangas L, Saario E, Bern David D et al. Treatment of acute Chlamydia pneumoniae infection with telithromycin in C57BL/6J mice. J Antimicrob Chemother 2004; 53: 1101–4.
- Carbon C, Moola S, Velancsics I et al. Telithromycin 800 mg once daily for seven to ten days is an effective and well-tol-erated treatment for community-acquired pneumonia. Clin Mi-crobiol Infect 2003; 9: 691–703.
- Koga H. High-performance liquid chromatography meas-urement of antimicrobial concentrations in polymorphonuclear leukocytes. Antimicrob Agents Chemother 1987; 31: 1904–8.
- Kunishima H, Takemura H, Yamamoto H et al. Evalua-tion of the activity of antimicrobial agents against Legionella pneumophila multiplying in a human monocytic cell line, THP-1, and an alveolar epithelial cell line, A549. J Infect Chemother 2000; 6: 206–10.
- Bosnar M, Kelneri6 Z, Muni 6 Vet al. Cellular uptake and efflux of azithromycin, erythromycin, clarithromycin, telithromycin, and cethromycin. Antimicrob Agents Chemother 2005; 49: 2372–7.
- Miossec-Bartoli C, Pilatre L, Peyron P et al. The new ke-tolide HMR 3647 accumulates in the azurophil granules of human polymorphonuclear cells. Antimicrob Agents Chemother 1999; 43: 2457–62.
- Vazifeh D, Labro MT. Investigation of the uptake of HMR 3647, HMR 3004 and roxithromycin by myelomonocytic cell lines. In: Abstracts of the 39th Interscience Conference on An-timicrobial Agents and Chemotherapy, San Francisco, CA, 1999. Abstract 1929. American Society for Microbiology, Wash-ington, DC, USA.